

6. Chapter 6: References

- ADAMS, J. M. & CORY, S. 2007. The Bcl-2 apoptotic switch in cancer development and therapy. *ONCOGENE*, 26, 1324-1337.
- ALLARD, B., ALLARD, D. & STAGG, J. 2016. Methods to evaluate the antitumor activity of immune checkpoint inhibitors in preclinical studies. *THE TUMOR MICROENVIRONMENT*. Springer.
- ALLARD, B., POMMEY, S., SMYTH, M. J. & STAGG, J. 2013. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. *CLINICAL CANCER RESEARCH*, 19, 5626-5635.
- ALLARD, B., TURCOTTE, M. & STAGG, J. 2012. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. *Journal of BIOMEDICINE AND BIOTECHNOLOGY*, 2012.
- ANAND, P., KUNNUMAKARA, A. B., SUNDARAM, C., HARIKUMAR, K. B., THARAKAN, S. T., LAI, O. S., SUNG, B. & AGGARWAL, B. B. 2008. Cancer is a preventable disease that requires major lifestyle changes. *PHARMACEUTICAL RESEARCH*, 25, 2097-2116.
- ANDERSEN, M. H., SCHRAMA, D., THOR STRATEN, P. & BECKER, J. C. 2006. Cytotoxic T cells. *JOURNAL OF INVESTIGATIVE DERMATOLOGY*, 126, 32-41.
- APETOH, L., GHIRINGHELLI, F., TESNIERE, A., OBEID, M., ORTIZ, C., CRIOLLO, A., MIGNOT, G., MAIURI, M. C., ULLRICH, E. & SAULNIER, P. 2007. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. *NATURE MEDICINE*, 13, 1050-1059.
- BAI, J., GAO, Z., LI, X., DONG, L., HAN, W. & NIE, J. 2017. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. *ONCOTARGET*, 8, 110693.
- BELL, C. W., JIANG, W., REICH III, C. F. & PISETSKY, D. S. 2006. The extracellular release of HMGB1 during apoptotic cell death. *AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY*, 291, C1318-C1325.
- BERTRAND, A., KOSTINE, M., BARNETCHE, T., TRUCHETET, M.-E. & SCHAEVERBEKE, T. 2015. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. *BMC MEDICINE*, 13, 1-14.
- BHOWMICK, N. A., NEILSON, E. G. & MOSES, H. L. 2004. Stromal fibroblasts in cancer initiation and progression. *NATURE*, 432, 332-337.
- BINDEA, G., MLECNIK, B., FRIDMAN, W.-H., PAGÈS, F. & GALON, J. 2010. Natural immunity to cancer in humans. *CURRENT OPINION IN IMMUNOLOGY*, 22, 215-222.
- BLASCO, M. A. 2005. Telomeres and human disease: ageing, cancer and beyond. *Nature REVIEWS GENETICS*, 6, 611-622.
- BORGHAEI, H., PAZ-ARES, L., HORN, L., SPIGEL, D. R., STEINS, M., READY, N. E., CHOW, L. Q., VOKES, E. E., FELIP, E. & HOLGADO, E. 2015. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *NEW ENGLAND JOURNAL OF MEDICINE*, 373, 1627-1639.
- BOUCK, N., STELLMACH, V. & HSU, S. C. 1996. How tumors become angiogenic. *ADVANCES IN CANCER RESEARCH*, 69, 135-174.
- BOURS, M., SWENNEN, E., DI VIRGILIO, F., CRONSTEIN, B. & DAGNELIE, P. 2006. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. *PHARMACOLOGY & THERAPEUTICS*, 112, 358-404.
- BRAHMER, J. R., TYKODI, S. S., CHOW, L. Q., HWU, W.-J., TOPALIAN, S. L., HWU, P., DRAKE, C. G., CAMACHO, L. H., KAUF, J. & ODUNSI, K. 2012.

- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *NEW ENGLAND JOURNAL OF MEDICINE*, 366, 2455-2465.
- BRYAN, T. M. & CECH, T. R. 1999. Telomerase and the maintenance of chromosome ends. *CURRENT OPINION IN CELL BIOLOGY*, 11, 318-324.
- CHAMBERS, A. F. & MATRISIAN, L. M. 1997. Changing views of the role of matrix metalloproteinases in metastasis. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*, 89, 1260-1270.
- CHENG, N., CHYTIL, A., SHYR, Y., JOLY, A. & MOSES, H. L. 2008. Transforming growth factor- β signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. *MOLECULAR CANCER RESEARCH*, 6, 1521-1533.
- CHEVOLET, I., SPEECKAERT, R., SCHREUER, M., NEYNS, B., KRYSKO, O., BACHERT, C., HENNART, B., ALLORGE, D., VAN GEEL, N. & VAN GELE, M. 2015. Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. *ONCOIMMUNOLOGY*, 4, e982382.
- CHRISTOFORI, G. & SEMB, H. 1999. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. *TRENDS IN BIOCHEMICAL SCIENCES*, 24, 73-76.
- CLEMENTE, C. G., MIHM JR, M. C., BUFALINO, R., ZURRIDA, S., COLLINI, P. & CASCINELLI, N. 1996. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. *CANCER: INTERDISCIPLINARY INTERNATIONAL JOURNAL OF THE AMERICAN CANCER SOCIETY*, 77, 1303-1310.
- COOK, D. G., PEACOCK, J. L., FEYERABEND, C., CAREY, I. M., JARVIS, M. J., ANDERSON, H. R. & BLAND, J. M. 1996. Relation of caffeine intake and blood caffeine concentrations during pregnancy to fetal growth: prospective population based study. *BMJ*, 313, 1358-1362.
- COUSSENS, L. M. & WERB, Z. 1996. Matrix metal loproteinases and the development of cancer. *CHEMISTRY & BIOLOGY*, 3, 895-904.
- CUBAS, R., MOSKALENKO, M., CHEUNG, J., YANG, M., MCNAMARA, E., XIONG, H., HOVES, S., RIES, C. H., KIM, J. & GOULD, S. 2018. Chemotherapy combines effectively with anti-PD-L1 treatment and can augment antitumor responses. *THE JOURNAL OF IMMUNOLOGY*, 201, 2273-2286.
- CURIEL, T. J., COUKOS, G., ZOU, L., ALVAREZ, X., CHENG, P., MOTTRAM, P., EVDEMON-HOGAN, M., CONEJO-GARCIA, J. R., ZHANG, L. & BUROW, M. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *NATURE MEDICINE*, 10, 942-949.
- CURRAN, M. A., MONTALVO, W., YAGITA, H. & ALLISON, J. P. 2010. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES*, 107, 4275-4280.
- DEBERARDINIS, R. J., LUM, J. J., HATZIVASSILIOU, G. & THOMPSON, C. B. 2008. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *CELL METABOLISM*, 7, 11-20.
- DREWNOWSKI, A. & REHM, C. D. 2016. Sources of caffeine in diets of US children and adults: trends by beverage type and purchase location. *NUTRIENTS*, 8, 154.
- EFFERTH, T., FABRY, U., GLATTE, P. & OSIEKA, R. 1995. Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic

- cells. *JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY*, 121, 648-656.
- EGEN, J. G., OUYANG, W. & WU, L. C. 2020. Human anti-tumor immunity: insights from immunotherapy clinical trials. *IMMUNITY*, 52, 36-54.
- EINI, H., FRISHMAN, V., YULZARI, R., KACHKO, L., LEWIS, E. C., CHAIMOVITZ, C. & DOUVDEVANI, A. 2015. Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor. *BIOCHEMICAL PHARMACOLOGY*, 98, 110-118.
- FERRIS, R. L., LICITRA, L., FAYETTE, J., EVEN, C., BLUMENSCHN, G., HARRINGTON, K. J., GUIGAY, J., VOKES, E. E., SABA, N. F. & HADDAD, R. 2019. Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use. *CLINICAL CANCER RESEARCH*, 25, 5221-5230.
- FERRONE, C. & DRANOFF, G. 2010. Dual roles for immunity in gastrointestinal cancers. *JOURNAL OF CLINICAL ONCOLOGY*, 28, 4045.
- FOLEY, K. P. & EISENMAN, R. N. 1999. Two MAD tails: what the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network. *BIOCHIMICA ET BIOPHYSICA ACTA (BBA)-REVIEWS ON CANCER*, 1423, M37-M47.
- FRIBERG, E., ORSINI, N., MANTZOROS, C. S. & WOLK, A. 2009. Coffee drinking and risk of endometrial cancer—A population-based cohort study. *INTERNATIONAL JOURNAL OF CANCER*, 125, 2413-2417.
- FUKUNAGA, A., MIYAMOTO, M., CHO, Y., MURAKAMI, S., KAWARADA, Y., OSHIKIRI, T., KATO, K., KUROKAWA, T., SUZUOKI, M. & NAKAKUBO, Y. 2004. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. *PANCREAS*, 28, e26-e31.
- GABRILOVICH, D. 2004. Mechanisms and functional significance of tumour-induced dendritic-cell defects. *NATURE REVIEWS IMMUNOLOGY*, 4, 941-952.
- GALLUZZI, L., SENOVILLA, L., ZITVOGEL, L. & KROEMER, G. 2012. The secret ally: immunostimulation by anticancer drugs. *Nature reviews Drug discovery*, 11, 215-233.
- GRAHAM, D. 1978. Caffeine--its identity, dietary sources, intake and biological effects. *NUTRITION REVIEWS*.
- HAMID, O., ROBERT, C., DAUD, A., HODI, F., HWU, W., KEFFORD, R., WOLCHOK, J., HERSEY, P., JOSEPH, R. & WEBER, J. 2019. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. *ANNALS OF ONCOLOGY*, 30, 582-588.
- HANAHAN, D. & FOLKMAN, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *CELL*, 86, 353-364.
- HANAHAN, D. & WEINBERG, R. A. 2000. The hallmarks of cancer. *CELL*, 100, 57-70.
- HANAHAN, D. & WEINBERG, R. A. 2011. Hallmarks of cancer: the next generation. *CELL*, 144, 646-674.
- HARTWELL, L. H. & KASTAN, M. B. 1994. Cell cycle control and cancer. *SCIENCE*, 266, 1821-1828.
- HERBST, R. S., SORIA, J.-C., KOWANETZ, M., FINE, G. D., HAMID, O., GORDON, M. S., SOSMAN, J. A., MCDERMOTT, D. F., POWDERLY, J. D. & GETTINGER, S. N. 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *NATURE*, 515, 563-567.
- HODI, F. S., O'DAY, S. J., MCDERMOTT, D. F., WEBER, R. W., SOSMAN, J. A., HAANEN, J. B., GONZALEZ, R., ROBERT, C., SCHADENDORF, D. &

- HASSEL, J. C. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. *NEW ENGLAND JOURNAL OF MEDICINE*, 363, 711-723.
- HOLICK, C. N., SMITH, S. G., GIOVANNUCCI, E. & MICHAUD, D. S. 2010. Coffee, tea, caffeine intake, and risk of adult glioma in three prospective cohort studies. *CANCER EPIDEMIOLOGY AND PREVENTION BIOMARKERS*, 19, 39-47.
- HOLMGAARD, R. B., ZAMARIN, D., MUNN, D. H., WOLCHOK, J. D. & ALLISON, J. P. 2013. Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. *JOURNAL OF EXPERIMENTAL MEDICINE*, 210, 1389-1402.
- HOUSE, S. W., WARBURG, O., BURK, D. & SCHADE, A. L. 1956. On respiratory impairment in cancer cells. *SCIENCE*, 124, 267-272.
- ISLAMI, F., GODING SAUER, A., MILLER, K. D., SIEGEL, R. L., FEDEWA, S. A., JACOBS, E. J., MCCULLOUGH, M. L., PATEL, A. V., MA, J. & SOERJOMATARAM, I. 2018. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. *CA: A CANCER JOURNAL FOR CLINICIANS*, 68, 31-54.
- JASS, J. 1986. Lymphocytic infiltration and survival in rectal cancer. *Journal of clinical pathology*, 39, 585-589.
- JIN, D., FAN, J., WANG, L., THOMPSON, L. F., LIU, A., DANIEL, B. J., SHIN, T., CURIEL, T. J. & ZHANG, B. 2010. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. *CANCER RESEARCH*, 70, 2245-2255.
- JOHNSON, J. P. 1991. Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. *CANCER AND METASTASIS REVIEWS*, 10, 11-22.
- JONES, R. G. & THOMPSON, C. B. 2009. Tumor suppressors and cell metabolism: a recipe for cancer growth. *Genes & development*, 23, 537-548.
- KIM, R. 2007. Cancer immunoediting: from immune surveillance to immune escape. *CANCER IMMUNOTHERAPY*, 9-27.
- KRUGER, S., ILMER, M., KOBOLD, S., CADILHA, B. L., ENDRES, S., ORMANNS, S., SCHUEBBE, G., RENZ, B. W., D'HAESE, J. G. & SCHLOESSER, H. 2019. Advances in cancer immunotherapy 2019–latest trends. *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH*, 38, 1-11.
- KUMAR, S., MALIK, S., SINGH, U. P., PONNAZHAGAN, S., SCISSUM-GUNN, K., MANNE, U. & MISHRA, M. K. 2017. PD-1 expression on Foxp3+ Treg cells modulates CD8+ T cell function in prostatic tumor microenvironment. *AM ASSOC IMMUNOL*.
- LAFLEUR, M. W., MUROYAMA, Y., DRAKE, C. G. & SHARPE, A. H. 2018. Inhibitors of the PD-1 pathway in tumor therapy. *THE JOURNAL OF IMMUNOLOGY*, 200, 375-383.
- LANITIS, E., DANGAJ, D., IRVING, M. & COUKOS, G. 2017. Mechanisms regulating T-cell infiltration and activity in solid tumors. *ANNALS OF ONCOLOGY*, 28, xii18-xii32.
- LARKIN, J., CHIARION-SILENI, V., GONZALEZ, R., GROB, J. J., COWEY, C. L., LAO, C. D., SCHADENDORF, D., DUMMER, R., SMYLLIE, M. & RUTKOWSKI, P. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *NEW ENGLAND JOURNAL OF MEDICINE*, 373, 23-34.
- LAXMANAN, S., ROBERTSON, S. W., WANG, E., LAU, J. S., BRISCOE, D. M. & MUKHOPADHYAY, D. 2005. Vascular endothelial growth factor impairs the

- functional ability of dendritic cells through Id pathways. *BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS*, 334, 193-198.
- LEBLANC, R., CATLEY, L. P., HIDESHIMA, T., LENTZSCH, S., MITSIADES, C. S., MITSIADES, N., NEUBERG, D., GOLOUBEVA, O., PIEN, C. S. & ADAMS, J. 2002. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. *CANCER RESEARCH*, 62, 4996-5000.
- LELO, A., MINERS, J. O., ROBSON, R. & BIRKETT, D. J. 1986. Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. *CLINICAL PHARMACOLOGY & THERAPEUTICS*, 39, 54-59.
- LIND, M. H., ROZELL, B., WALLIN, R. P., VAN HOGERLINDEN, M., LJUNGGREN, H.-G., TOFTGÅRD, R. & SUR, I. 2004. Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF- κ B inhibition. *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES*, 101, 4972-4977.
- LOWE, S. W., CEPERO, E. & EVAN, G. 2004. Intrinsic tumour suppression. *Nature*, 432, 307-315.
- LUCKHEERAM, R. V., ZHOU, R., VERMA, A. D. & XIA, B. 2012. CD4⁺ T cells: differentiation and functions. *CLINICAL AND DEVELOPMENTAL IMMUNOLOGY*, 2012.
- MA, S.-R., DENG, W.-W., LIU, J.-F., MAO, L., YU, G.-T., BU, L.-L., KULKARNI, A. B., ZHANG, W.-F. & SUN, Z.-J. 2017. Blockade of adenosine A2A receptor enhances CD8⁺ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. *MOLECULAR CANCER*, 16, 1-15.
- MADAN, V., LEAR, J. T. & SZEIMIES, R.-M. 2010. Non-melanoma skin cancer. *The lancet*, 375, 673-685.
- MAEURER, M. J., GOLLIN, S. M., MARTIN, D., SWANEY, W., BRYANT, J., CASTELLI, C., ROBBINS, P., PARMIANI, G., STORKUS, W. J. & LOTZE, M. T. 1996. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. *THE JOURNAL OF CLINICAL INVESTIGATION*, 98, 1633-1641.
- MATHUR, P., SATHISHKUMAR, K., CHATURVEDI, M., DAS, P., SUDARSHAN, K. L., SANTHAPPAN, S., NALLASAMY, V., JOHN, A., NARASIMHAN, S. & ROSELIND, F. S. 2020. Cancer statistics, 2020: report from national cancer registry programme, India. *JCO GLOBAL ONCOLOGY*, 6, 1063-1075.
- MCCUNE, J. 2016. Immunotherapy to treat cancer. Wiley Online Library.
- MCLELLAN, T. M., CALDWELL, J. A. & LIEBERMAN, H. R. 2016. A review of caffeine's effects on cognitive, physical and occupational performance. *NEUROSCIENCE & BIOBEHAVIORAL REVIEWS*, 71, 294-312.
- MEMPEL, T. R., PITTET, M. J., KHAZAIE, K., WENINGER, W., WEISSLEDER, R., VON BOEHMER, H. & VON ANDRIAN, U. H. 2006. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. *IMMUNITY*, 25, 129-141.
- MENGER, L., VACCHELLI, E., ADJEMIAN, S., MARTINS, I., MA, Y., SHEN, S., YAMAZAKI, T., SUKKURWALA, A. Q., MICHAUD, M. & MIGNOT, G. 2012. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. *SCIENCE TRANSLATIONAL MEDICINE*, 4, 143ra99-143ra99.
- MERIGHI, S., BENINI, A., MIRANDOLA, P., GESSI, S., VARANI, K., SIMIONI, C., LEUNG, E., MACLENNAN, S., BARALDI, P. G. & BOREA, P. A. 2007.

- Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1 α , vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. *MOLECULAR PHARMACOLOGY*, 72, 395-406.
- MOSMANN, T. R. & COFFMAN, R. L. 1989. Heterogeneity of cytokine secretion patterns and functions of helper T cells. *ADVANCES IN IMMUNOLOGY*, 46, 111-147.
- MOTZER, R. J., ESCUDIER, B., MCDERMOTT, D. F., GEORGE, S., HAMMERS, H. J., SRINIVAS, S., TYKODI, S. S., SOSMAN, J. A., PROCOPIO, G. & PLIMACK, E. R. 2015. Nivolumab versus everolimus in advanced renal-cell carcinoma. *NEW ENGLAND JOURNAL OF MEDICINE*, 373, 1803-1813.
- MOUGIAKAKOS, D., CHOUDHURY, A., LLADSER, A., KIESSLING, R. & JOHANSSON, C. C. 2010. Regulatory T cells in cancer. *ADVANCES IN CANCER RESEARCH*, 107, 57-117.
- NAGORSEN, D., SCHEIBENBOGEN, C., MARINCOLA, F. M., LETSCH, A. & KEILHOLZ, U. 2003. Natural T cell immunity against cancer. *CLINICAL CANCER RESEARCH*, 9, 4296-4303.
- NAIDOO, J., PAGE, D., LI, B. T., CONNELL, L. C., SCHINDLER, K., LACOUTURE, M. E., POSTOW, M. A. & WOLCHOK, J. 2015. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. *ANNALS OF ONCOLOGY*, 26, 2375-2391.
- NAIR, A. B. & JACOB, S. 2016. A simple practice guide for dose conversion between animals and human. *JOURNAL OF BASIC AND CLINICAL PHARMACY*, 7, 27.
- NAITO, Y., SAITO, K., SHIIBA, K., OHUCHI, A., SAIGENJI, K., NAGURA, H. & OHTANI, H. 1998. CD8⁺ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. *CANCER RESEARCH*, 58, 3491-3494.
- NASTOUPIL, L. J., ROSE, A. C. & FLOWERS, C. R. 2012. Diffuse large B-cell lymphoma: current treatment approaches. *ONCOLOGY*, 26, 488.
- NELSON, B. H. 2008. The impact of T-cell immunity on ovarian cancer outcomes. *IMMUNOLOGICAL REVIEWS*, 222, 101-116.
- NKONDJOCK, A. 2009. Coffee consumption and the risk of cancer: an overview. *CANCER LETTERS*, 277, 121-125.
- NURSE, P. 1994. Ordering S phase and M phase in the cell cycle. *Cell*, 79, 547-550.
- OBA, S., SHIMIZU, N., NAGATA, C., SHIMIZU, H., KAMETANI, M., TAKEYAMA, N., OHNUMA, T. & MATSUSHITA, S. 2006. The relationship between the consumption of meat, fat, and coffee and the risk of colon cancer: a prospective study in Japan. *CANCER LETTERS*, 244, 260-267.
- OBEID, M., PANARETAKIS, T., TESNIERE, A., JOZA, N., TUFI, R., APETO, L., GHIRINGHELLI, F., ZITVOGEL, L. & KROEMER, G. 2007a. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. *CANCER RESEARCH*, 67, 7941-7944.
- OBEID, M., TESNIERE, A., GHIRINGHELLI, F., FIMIA, G. M., APETO, L., PERFETTINI, J.-L., CASTEDO, M., MIGNOT, G., PANARETAKIS, T. & CASARES, N. 2007b. Calreticulin exposure dictates the immunogenicity of cancer cell death. *NATURE MEDICINE*, 13, 54-61.
- OHTA, A., GORELIK, E., PRASAD, S. J., RONCHESE, F., LUKASHEV, D., WONG, M. K., HUANG, X., CALDWELL, S., LIU, K. & SMITH, P. 2006. A2A adenosine receptor protects tumors from antitumor T cells. *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES*, 103, 13132-13137.

- OSTRAND-ROSENBERG, S. & SINHA, P. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. *The Journal of Immunology*, 182, 4499-4506.
- OVERWIJK, W. W. & RESTIFO, N. P. 2000. B16 as a mouse model for human melanoma. *CURRENT PROTOCOLS IN IMMUNOLOGY*, 39, 20.1. 1-20.1. 29.
- PAGES, F., GALON, J., DIEU-NOSJEAN, M., TARTOUR, E., SAUTES-FRIDMAN, C. & FRIDMAN, W. 2010. Immune infiltration in human tumors: a prognostic factor that should not be ignored. *ONCOGENE*, 29, 1093-1102.
- PARDOLL, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. *NATURE REVIEWS CANCER*, 12, 252-264.
- PASCHE, B. 2001. Role of transforming growth factor beta in cancer. *JOURNAL OF CELLULAR PHYSIOLOGY*, 186, 153-168.
- PAZDUR, R. 2008. Endpoints for assessing drug activity in clinical trials. *THE ONCOLOGIST*, 13, 19-21.
- PFIRSCHKE, C., ENGBLOM, C., RICKELT, S., CORTEZ-RETAMOZO, V., GARRIS, C., PUCCI, F., YAMAZAKI, T., POIRIER-COLAME, V., NEWTON, A. & REDOUANE, Y. 2016. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. *IMMUNITY*, 44, 343-354.
- POSTOW, M. A., CHESNEY, J., PAVLICK, A. C., ROBERT, C., GROSSMANN, K., MCDERMOTT, D., LINETTE, G. P., MEYER, N., GIGUERE, J. K. & AGARWALA, S. S. 2015. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *NEW ENGLAND JOURNAL OF MEDICINE*, 372, 2006-2017.
- PREDIGER, R. D. 2010. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. *JOURNAL OF ALZHEIMER'S DISEASE*, 20, S205-S220.
- RAMPLING, R., JAMES, A. & PAPANASTASSIOU, V. 2004. The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. *JOURNAL OF NEUROLOGY, NEUROSURGERY & PSYCHIATRY*, 75, ii24-ii30.
- RAN, L., LIU, W., FANG, Y., XU, S., LI, J., LUO, X., PAN, D., WANG, M. & WANG, W. 2021. Alcohol, coffee and tea intake and the risk of cognitive deficits: a dose-response meta-analysis. *EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES*, 30.
- RECK, M., RODRÍGUEZ-ABREU, D., ROBINSON, A. G., HUI, R., CSÖSZI, T., FÜLÖP, A., GOTTFRIED, M., PELED, N., TAFRESHI, A. & CUFFE, S. 2016. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N ENGL J MED*, 375, 1823-1833.
- RIZVI, N. A., HELLMANN, M. D., SNYDER, A., KVISTBORG, P., MAKAROV, V., HAVEL, J. J., LEE, W., YUAN, J., WONG, P. & HO, T. S. 2015. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *SCIENCE*, 348, 124-128.
- ROBERT, C., SCHACHTER, J., LONG, G. V., ARANCE, A., GROB, J. J., MORTIER, L., DAUD, A., CARLINO, M. S., MCNEIL, C. & LOTEM, M. 2015. Pembrolizumab versus ipilimumab in advanced melanoma. *New England Journal of Medicine*, 372, 2521-2532.
- SADZUKA, Y., MOCHIZUKI, E., IWAZAKI, A., HIROTA, S. & TAKINO, Y. 1995a. Caffeine enhances adriamycin antitumor activity in Ehrlich ascites carcinoma-bearing mice. *BIOLOGICAL AND PHARMACEUTICAL BULLETIN*, 18, 159-161.
- SADZUKA, Y., MOCHIZUKI, E. & TAKINO, Y. 1995b. Mechanism of caffeine modulation of the antitumor activity of adriamycin. *TOXICOLOGY LETTERS*, 75, 39-49.

- SATO, E., OLSON, S. H., AHN, J., BUNDY, B., NISHIKAWA, H., QIAN, F., JUNGBLUTH, A. A., FROSINA, D., GNJATIC, S. & AMBROSONE, C. 2005. Intraepithelial CD8⁺ tumor-infiltrating lymphocytes and a high CD8⁺/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES*, 102, 18538-18543.
- SEMENZA, G. L. 2010. HIF-1: upstream and downstream of cancer metabolism. *CURRENT OPINION IN GENETICS & DEVELOPMENT*, 20, 51-56.
- SHALAPOUR, S., FONT-BURGADA, J., DI CARO, G., ZHONG, Z., SANCHEZ-LOPEZ, E., DHAR, D., WILLIMSKY, G., AMMIRANTE, M., STRASNER, A. & HANSEL, D. E. 2015. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. *NATURE*, 521, 94-98.
- SHAPIRO, G. I. & HARPER, J. W. 1999. Anticancer drug targets: cell cycle and checkpoint control. *THE JOURNAL OF CLINICAL INVESTIGATION*, 104, 1645-1653.
- SHARMA, P., HU-LIESKOVAN, S., WARGO, J. A. & RIBAS, A. 2017. Primary, adaptive, and acquired resistance to cancer immunotherapy. *CELL*, 168, 707-723.
- SHAY, J. W. & BACCHETTI, S. 1997. A survey of telomerase activity in human cancer. *EUROPEAN JOURNAL OF CANCER*, 33, 787-791.
- SHAY, J. W. & WRIGHT, W. E. 2000. Hayflick, his limit, and cellular ageing. *NATURE REVIEWS MOLECULAR CELL BIOLOGY*, 1, 72-76.
- SHI, D. & DALY, J. W. 1999. Chronic effects of xanthines on levels of central receptors in mice. *CELLULAR AND MOLECULAR NEUROBIOLOGY*, 19, 719-732.
- SHIELDS, J. D., KOURTIS, I. C., TOMEI, A. A., ROBERTS, J. M. & SWARTZ, M. A. 2010. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. *SCIENCE*, 328, 749-752.
- SHIRATSUCHI, A., WATANABE, I., TAKEUCHI, O., AKIRA, S. & NAKANISHI, Y. 2004. Inhibitory effect of Toll-like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages. *THE JOURNAL OF IMMUNOLOGY*, 172, 2039-2047.
- SIAMOF, C. M., GOEL, S. & CAI, W. 2020. Moving beyond the pillars of cancer treatment: perspectives from nanotechnology. *FRONTIERS IN CHEMISTRY*, 8.
- SINGH, R. K., GUTMAN, M., BUCANA, C. D., SANCHEZ, R., LLANSA, N. & FIDLER, I. J. 1995. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES*, 92, 4562-4566.
- SITKOVSKY, M. V., LUKASHEV, D., APASOV, S., KOJIMA, H., KOSHIBA, M., CALDWELL, C., OHTA, A. & THIEL, M. 2004. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. *ANNU. REV. IMMUNOL.*, 22, 657-682.
- SONG, F., QURESHI, A. A. & HAN, J. 2012. Increased caffeine intake is associated with reduced risk of basal cell carcinoma of the skin. *CANCER RESEARCH*, 72, 3282-3289.
- STAGG, J., DIVISEKERA, U., DURET, H., SPARWASSER, T., TENG, M. W., DARCY, P. K. & SMYTH, M. J. 2011. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. *CANCER RESEARCH*, 71, 2892-2900.
- SUN, F., CUI, L., LI, T., CHEN, S., SONG, J. & LI, D. 2019. Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma. *JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION*, 39, 208-214.

- SUNG, H., FERLAY, J., SIEGEL, R. L., LAVERSANNE, M., SOERJOMATARAM, I., JEMAL, A. & BRAY, F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A CANCER JOURNAL FOR CLINICIANS*, 71, 209-249.
- SWANN, J. B. & SMYTH, M. J. 2007. Immune surveillance of tumors. *THE JOURNAL OF CLINICAL INVESTIGATION*, 117, 1137-1146.
- TEJ, G. N. V. C. & NAYAK, P. K. 2018. Mechanistic considerations in chemotherapeutic activity of caffeine. *BIOMEDICINE & PHARMACOTHERAPY*, 105, 312-319.
- TENG, M. W., SWANN, J. B., KOEBEL, C. M., SCHREIBER, R. D. & SMYTH, M. J. 2008. Immune-mediated dormancy: an equilibrium with cancer. *JOURNAL OF LEUKOCYTE BIOLOGY*, 84, 988-993.
- TESNIERE, A., SCHLEMMER, F., BOIGE, V., KEPP, O., MARTINS, I., GHIRINGHELLI, F., AYMERIC, L., MICHAUD, M., APETOH, L. & BARAULT, L. 2010. Immunogenic death of colon cancer cells treated with oxaliplatin. *ONCOGENE*, 29, 482-491.
- TOPALIAN, S. L., HODI, F. S., BRAHMER, J. R., GETTINGER, S. N., SMITH, D. C., MCDERMOTT, D. F., POWDERLY, J. D., CARVAJAL, R. D., SOSMAN, J. A. & ATKINS, M. B. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *NEW ENGLAND JOURNAL OF MEDICINE*, 366, 2443-2454.
- TUMEH, P. C., HARVIEW, C. L., YEARLEY, J. H., SHINTAKU, I. P., TAYLOR, E. J., ROBERT, L., CHMIELOWSKI, B., SPASIC, M., HENRY, G. & CIOBANU, V. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *NATURE*, 515, 568-571.
- VAJDIC, C. M. & VAN LEEUWEN, M. T. 2009. Cancer incidence and risk factors after solid organ transplantation. *INTERNATIONAL JOURNAL OF CANCER*, 125, 1747-1754.
- VIGANO, S., ALATZOGLOU, D., IRVING, M., MÉNÉTRIÉ-CAUX, C., CAUX, C., ROMERO, P. & COUKOS, G. 2019. Targeting adenosine in cancer immunotherapy to enhance T-cell function. *FRONTIERS IN IMMUNOLOGY*, 10, 925.
- VINAY, D. S., RYAN, E. P., PAWELEC, G., TALIB, W. H., STAGG, J., ELKORD, E., LICHTOR, T., DECKER, W. K., WHELAN, R. L. & KUMARA, H. S. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *SEMINARS IN CANCER BIOLOGY*, 2015. Elsevier, S185-S198.
- VOLPERT, O. V., DAMERON, K. M. & BOUCK, N. 1997. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. *ONCOGENE*, 14, 1495-1502.
- WANG, W., WU, L., ZHANG, J., WU, H., HAN, E. & GUO, Q. 2017. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model. *BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS*, 487, 1-7.
- WARBURG, O. 1956. On the origin of cancer cells. *SCIENCE*, 123, 309-314.
- WARBURG, O. H. 1930. The metabolism of tumours: investigations from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlem, CONSTABLE & COMPANY LIMITED.
- WERB, Z. 1997. ECM and cell surface proteolysis: regulating cellular ecology. *CELL*, 91, 439-442.

- WHITESIDE, T. L. 2017. Targeting adenosine in cancer immunotherapy: a review of recent progress. *EXPERT REVIEW OF ANTICANCER THERAPY*, 17, 527-535.
- WILLIS, S. N. & ADAMS, J. M. 2005. Life in the balance: how BH3-only proteins induce apoptosis. *CURRENT OPINION IN CELL BIOLOGY*, 17, 617-625.
- WOLCHOK, J. D., KLUGER, H., CALLAHAN, M. K., POSTOW, M. A., RIZVI, N. A., LESOKHIN, A. M., SEGAL, N. H., ARIYAN, C. E., GORDON, R.-A. & REED, K. 2013. Nivolumab plus ipilimumab in advanced melanoma. *N ENGL J MED*, 369, 122-133.
- WOO, S.-R., TURNIS, M. E., GOLDBERG, M. V., BANKOTI, J., SELBY, M., NIRSCHL, C. J., BETTINI, M. L., GRAVANO, D. M., VOGEL, P. & LIU, C. L. 2012. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. *CANCER RESEARCH*, 72, 917-927.
- XIE, K. 2001. Interleukin-8 and human cancer biology. *CYTOKINE & GROWTH FACTOR REVIEWS*, 12, 375-391.
- YANG, L., PANG, Y. & MOSES, H. L. 2010. TGF- β and immune cells: an important regulatory axis in the tumor microenvironment and progression. *TRENDS IN IMMUNOLOGY*, 31, 220-227.
- YILDIZHAN, H., BARKAN, N. P., TURAN, S. K., DEMIRALP, Ö., DEMIRALP, F. D. Ö., USLU, B. & ÖZKAN, S. A. 2018. Treatment strategies in cancer from past to present. *DRUG TARGETING AND STIMULI SENSITIVE DRUG DELIVERY SYSTEMS*. Elsevier.
- YOKOKAWA, J., CEREDA, V., REMONDO, C., GULLEY, J. L., ARLEN, P. M., SCHLOM, J. & TSANG, K. Y. 2008. Enhanced functionality of CD4⁺ CD25^{high} FoxP3⁺ regulatory T cells in the peripheral blood of patients with prostate cancer. *CLINICAL CANCER RESEARCH*, 14, 1032-1040.
- ZABELINA, D. L. & SILVIA, P. J. 2020. Percolating ideas: The effects of caffeine on creative thinking and problem solving. *CONSCIOUSNESS AND COGNITION*, 79, 102899.
- ZHAO, Y.-J., ZHANG, J., SHI, F., HU, Z.-P., WU, J.-P., WU, G.-J., WANG, R.-B., ZHOU, Q., CHANG, H. & LI, Y.-N. 2018. Expression of PD-1 on CD4⁺ tumor-infiltrating lymphocytes in tumor microenvironment associated with pathological characteristics of breast cancer. *JOURNAL OF IMMUNOLOGY RESEARCH*, 2018.
- ZHOU, J., KANG, Y., CHEN, L., WANG, H., LIU, J., ZENG, S. & YU, L. 2020. The drug-resistance mechanisms of five platinum-based antitumor agents. *FRONTIERS IN PHARMACOLOGY*, 11, 343.
- ZHOU, J., WANG, G., CHEN, Y., WANG, H., HUA, Y. & CAI, Z. 2019. Immunogenic cell death in cancer therapy: Present and emerging inducers. *JOURNAL OF CELLULAR AND MOLECULAR MEDICINE*, 23, 4854-4865.
- ZHU, J. & PAUL, W. E. 2008. CD4 T cells: fates, functions, and faults. *Blood, THE JOURNAL OF THE AMERICAN SOCIETY OF HEMATOLOGY*, 112, 1557-1569.
- ZITVOGEL, L., GALLUZZI, L., SMYTH, M. J. & KROEMER, G. 2013. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. *IMMUNITY*, 39, 74-88.
- ZOU, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. *NATURE REVIEWS IMMUNOLOGY*, 6, 295-307.
- ZOU, W., WOLCHOK, J. D. & CHEN, L. 2016. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. *SCIENCE TRANSLATIONAL MEDICINE*, 8, 328rv4-328rv4.